



The
Patent
Office

PCT/GB00/00262



INVESTOR IN PEOPLE

GB00/263

REC'D 21 FEB 2000
WIPO PCT

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 1 February 2000

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



nts Form 1/77

Patents Act 1977
(Rule 16)

The
**Patent
Office**

1/77

29JAN99 E421386-1 D00011
F01/7700 0.00 - 9901902.8

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1.	Your reference	SCB/52068/000		
2.	Patent application number (The Patent Office will fill in this part)	28 JAN 1999	9901902.8	
3.	Full name, address and postcode of the or of each applicant (underline all surnames)	ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE UNIVERSITY OF LONDON EGHAM SURREY TW20 0EX		
	Patents ADP number (if you know it)			
	If the applicant is a corporate body, give the country/state of its incorporation	UNITED KINGDOM		
4.	Title of the invention	MANIPULATING ISOPRENOID EXPRESSION		
5.	Name of your agent (if you have one)	BOULT WADE TENNANT		
	"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	27 FURNIVAL STREET		
		LONDON		
		EC4A 1PQ		
	Patents ADP number (if you know it)	42001		
6.	If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day/month/year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)	
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	YES		

Patents Form 1/77

9. Enter the number of sheets of any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 29

Claim(s) 5

Abstract 0

Drawing(s) 5 *rs*

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (Please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Boulton Wade Clement

Date

28 January 1999

12. Name and daytime telephone number of person to contact in the United Kingdom COLM D. MURPHY
0171 404 5921

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

MANIPULATING ISOPRENOID EXPRESSION

5 The present invention is concerned with manipulating or altering isoprenoid expression in a cell or organism which biosynthesises isopentenyl diphosphate (IPP), which is the universal precursor of all isoprenoids in nature, via a mevalonate independent pathway.

10 Isoprenoids constitute the largest class of natural products occurring in nature, with over 29,000 individual compounds identified to date [1]. Chemically, they are extremely diverse in their structure and complexity. The fundamental biological
15 functions performed by isoprenoids ensure they are essential for the normal growth and developmental processes in all living organisms. These include functioning as eukaryotic membrane stabilisers (sterols), plant hormones (gibberellins and abscisic
20 acid), providing pigments for photosynthesis (carotenoids and phytol side chain of chlorophyll), and as carriers for electron transport (menaquinone, plastoquinone and ubiquinone).

25 All isoprenoids are synthesised via a common metabolic precursor, isopentenyl diphosphate (IPP; C₅). Until recently, the biosynthesis of IPP was generally assumed to proceed exclusively from acetyl-CoA via the classical mevalonate pathway (Fig. 1) [2]. The enzyme
30 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) catalyses the conversion of hydroxymethylglutaryl-CoA to mevalonate, a key reaction of the mevalonate-dependant IPP biosynthetic pathway. Recent studies have demonstrated that mevalonate is not the
35 biosynthetic precursor of IPP in all living organisms

[3,4]. The existence of an alternative, mevalonate-independent pathway for IPP formation was identified initially in several species of eubacteria [4,5] and a green alga [6]. The pathway was
5 subsequently shown to be operational in the plastids of higher plants [7-10]. The first reaction in the non-mevalonate pathway is the transketolase-type condensation reaction of pyruvate and D-glyceraldehyde-3-phosphate to yield
10 1-deoxy-D-xylulose-5-phosphate (DXP) (Fig. 1). This reaction is catalysed by the enzyme 1-deoxy-D-xylulose-5-phosphate synthase. The second reaction in the pathway is the conversion of DXP to 2-C-methyl-D-erythritol-4-phosphate (MEP). The reactions which
15 convert MEP to IPP have yet to be characterised.

The cloning and characterisation of the DXP synthase (*dxps*) gene has been described for a number of organisms including *Escherichia coli* [11,12] and higher
20 plants [13-15]. The *CLA1* gene product from *Arabidopsis thaliana* associated with chloroplast development [16], for example, has been shown to exhibit *DXPS* activity [11]. Recently, a gene responsible for the reduction of DXP to
25 2-C-methyl-D-erythritol-4-phosphate, the proposed next step in the non-mevalonate pathway has been cloned from *E. coli* [17].

The present inventors have surprisingly found that the
30 first reaction in the mevalonate-independent IPP biosynthetic pathway is highly influential in controlling the levels of isoprenoids which can be formed in a cell or organism within which the mevalonate independent IPP biosynthetic pathway is
35 present. The enzyme *DXPS* or functional equivalents

thereof, has been identified by the present inventors as a rate-limiting step in isoprenoid biosynthesis and that DXPS activity plays an important role in channelling the carbon resources of the cell into the isoprenoid biosynthetic pathway.

Therefore, according to a first aspect of the present invention there is provided a method of manipulating isoprenoid expression in a cell possessing a mevalonate independent isopentenyl diphosphate synthesising pathway, which method comprises altering the activity of the enzyme 1-deoxy-D-xylulose-5-phosphate synthase (DXPS), or a functional equivalent thereof. Thus, advantageously, the rate-limiting effect conferred by DXPS activity on the IPP biosynthetic pathway can be utilised to manipulate the resultant levels of isoprenoids in a cell by altering the activity or expression of DXPS.

Preferably, the levels of isoprenoids in a cell can be enhanced by increasing the activity or expression of the DXPS. Likewise reduced levels of isoprenoids can be achieved by reducing or inhibiting activity or expression of DXPS in a cell or organism. Increasing the DXPS activity may be achieved by, for example, transforming the cell which may itself be part of a cell line or an organism with an expression vector comprising a nucleic acid molecule encoding DXPS, which may advantageously be operably linked to a reporter molecule, such as used in the GUS assay which is known in the art. Preferably, the vector comprises any of the vectors designated pBSDXPS or pSYDXPS, illustrated in Figure 2.

An alternative method for altering expression may comprise utilising a technique known as Enforced Evolution, or DNA Shuffling see Patten et al. Current Opinion in Biotechnology, 1997, Vol. 8, No. 6, pp 724-733, Cramer et al., Nature 1998, Vol. 391, No. 6664, pp 288-291 and Harayama S, Trends in Biotechnology, 1998, Vol. 16, No. 2, pp 76-82. According to this method improvements in enzyme activity can be achieved by reassembling DNA segments into a full length gene by homologous or site specific combination. Before the assembly, the segments are often subjected to random mutagenesis by error prone PCR, random nucleotide insertion, or other such methods. The genes can be expressed in suitable microbial hosts leading to the production of functional polypeptides, such as DXPS.

The nucleic acid encoding the DXPS may be endogenous to the cell or organism into which it will be transformed or, alternatively, may be exogenous. In one embodiment of the invention, the method may also comprise transforming the cell or organism with a vector comprising one or more nucleic acid sequences suitable for producing a desired isoprenoid. This aspect of the invention is particularly advantageous because it allows isoprenoids to be produced in a cell or organism independent of the source of the isoprenoid which may be derived from cells or organisms which do not possess the mevalonate independent IPP biosynthesising pathway. Similarly, enhanced levels of an isoprenoid can be produced in cells or organisms having the mevalonate independent IPP biosynthetic pathway.

Therefore, in the example where the cell is *E. coli* it is possible to engineer production of an isoprenoid which is exogenous to the *E. coli* bacterium, which isoprenoid may be, for example, any of the carotenoids of plants, such as, lycopene or even an isoprenoid of human origin.

Carotenoids are yellow-orange-red lipid based pigments found in nature. They have been found to be useful in a variety of applications, for example, as supplements, and particularly vitamin supplements, as vegetable oil based food products and food ingredients, as feed additives in animal feeds and as colorants. Phytoene has been found to be useful in treating skin disorders whilst lycopene and α and β carotene consumption have been implicated as having preventative effects against certain kinds of cancers. Therefore, it is a highly advantageous aspect of the invention that increased production of such compounds can be achieved and which compounds can confer considerable health care benefits. Once the desired carotenoid or other isoprenoid has been produced in *E. coli*, or other suitable organism as defined above, it can be isolated using standard bioengineering techniques.

Increases in concentrations of any desired isoprenoid may be achieved, in a cell or alternatively an organism which possesses the IPP biosynthetic mevalonate independent pathway. For example, crops can be engineered using the method of the invention to produce increased levels of an isoprenoid which confers nutritional benefits to humans following consumption of the plant, such as, for example, vitamin E and lycopene.

Therefore, there is also provided by a further aspect of the invention a cell or organism having a mevalonate independent IPP biosynthetic pathway and which has been transformed or transfected with an expression vector comprising a nucleic acid molecule encoding DXPS or a functional equivalent or bioprecursor thereof. As described above, the vector may also include one or more further nucleic acid sequences suitable for producing a desired isoprenoid, or alternatively the one or more nucleic acid sequences may be included in a separate vector, operably linked to suitable expression control sequences.

An expression vector according to the invention includes a vector having a nucleic acid sequence operably linked to regulatory sequences, such as promoter regions, that are capable of effecting expression of said DNA fragments. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. Such vectors may be transformed into a suitable host cell or organism to produce a desired protein, such as DXPS or an isoprenoid according to the method of the invention. Thus, in a further aspect, the invention provides a process for producing a desired isoprenoid which comprises cultivating a host cell, transformed or transfected with an expression vector as described above under conditions to provide for expression by the vector of DXPS or a functional equivalent thereof or suitable polypeptides for producing a desired isoprenoid and optionally recovering the expressed polypeptides.

The vectors may be, for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of said nucleotide and optionally a regulator of the promoter.

5 The vectors may contain one or more selectable markers, such as, for example, ampicillin resistance.

Regulatory elements required for expression include promoter sequences to bind RNA polymerase and

10 transcription initiation sequences for ribosome binding. For example, a bacterial expression vector may include a promoter such as the lac promoter and for transcription initiation in the Shine-Dalgarno sequence and the start codon AUG. Similarly, a

15 eukaryotic expression vector may include a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such vectors may be obtained

20 commercially or assembled from the sequences described by methods well known in the art.

By combining the nucleic acid sequences encoding said DXPS and optionally the one or more sequences suitable

25 for producing an isoprenoid with tissue specific promoters, enhanced isoprenoid levels in specified tissues of plants can be achieved. For example, by utilising a seed specific promoter or other transcriptional initiation region, elevated levels of

30 carotenoids in seeds may be achieved. The seed can then be harvested and which provides a reservoir for the isoprenoid or carotenoid of interest.

Generally, the nucleic acid molecule encoding said

35 DXPS which is included in the vector used in

accordance with the method of the invention, will be directed to the plastids of the plant. Accordingly, where the vector is not inserted directly into the plastid of the plant, the vector will further comprise
5 a nucleic acid sequence operably linked to said DXPS or said one or more isoprenoid producing nucleic acid sequences and which further sequence will encode a transit peptide to direct expression of the DXPS or isoprenoid into the plastid. Native or heterologous
10 transit peptides may be utilised in this embodiment of the invention.

As aforesaid, the mevalonate independent IPP biosynthetic pathway is not present in any higher
15 animals, particularly humans. Therefore, the inhibition of the reaction catalysed by DXPS provides a unique target site to selectively inhibit or alleviate bacterial associated infections by altering the expression level of or inhibiting function or
20 activity of DXPS.

One method of inhibiting or preventing expression of DXPS utilises antisense technology. Antisense technology can be used to control gene expression
25 through helix formation of antisense DNA or RNA, both of which methods are based on polynucleotide binding to DNA or RNA. For example, the 5'-coding region of a native DNA sequence coding for DXPS according to the invention may be used to design an antisense RNA
30 nucleotide of from 10 to 50 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple-helix - see Lee et al, Nucl. Acids. Res., 6:3073 (1979); Cooney et al., Science, 241:456 (1988);
35 and Derman et al., Science 251:1360 (1991), in which

case expression of the antisense RNA oligonucleotide allows hybridisation to the mRNA *in vivo* and blocks translation of an mRNA molecule into DXPS.

- 5 Alternatively, compounds can be screened for their ability to inhibit the catalytic activity or expression of DXPS in the mevalonate - independent IPP biosynthetic pathway. According to a further aspect of the invention, therefore, there is also provided a
- 10 method of identifying a compound which modulates isoprenoid production or expression which method comprises contacting said compound to be tested with a molecule from the mevalonate independent IPP biosynthetic pathway and which molecule undergoes a
- 15 reaction in the presence of an appropriate reactant catalysed by DXPS, in the presence of DXPS and monitoring the level of product produced when compared to the same reaction in the absence of the compound to be tested. Preferably, the molecules which are
- 20 reacted are pyruvate and glyceraldehyde-3-phosphate, and which undergo a condensation reaction in the presence of DXPS, to yield 1-deoxy-D-xylulose-5-phosphate (DXP) as illustrated in Figure 1.
- 25 Any compounds identified as preventing expression or activity of the DXPS enzyme according to the invention may advantageously be particularly useful as selective toxicity agents to destroy, for example, bacterial or plant cells which possess the mevalonate independent
- 30 IPP biosynthetic pathway. These compounds therefore can be particularly useful as medicaments or herbicides, or alternatively in the preparation of a medicament for treating bacterial associated diseases.

A further aspect of the invention therefore also comprises a pharmaceutical composition comprising a compound identified as an inhibitor of expression or activity of DXPS or a functional equivalent or bioprecursor thereof, together with a pharmaceutically acceptable carrier, diluent or excipient thereof. Also provided by the invention is a herbicidal composition comprising said compound identified as an inhibitor of expression or activity of DXPS function.

10

An even further aspect of the invention comprises a transgenic cell, tissue or organism having a mevalonate independent IPP biosynthetic pathway, which comprises a transgene capable of expressing at least one additional DXPS molecule according to the invention. The transgenic cell, tissue or organism may also comprise a transgene having one or more nucleic acid sequences capable of producing a desired isoprenoid.

20

The term "transgene capable of expression" as used herein means a suitable nucleic acid sequence(s) which leads to expression of DXPS or proteins having the same function and/or activity and/or encoding proteins capable of producing a desired isoprenoid. The transgene, may include, for example, isolated genomic nucleic acid or synthetic nucleic acid, including DNA integrated into the genome. Preferably, the transgene comprises the nucleic acid sequence(s) encoding the DXPS enzyme or said isoprenoid as described herein, or a functional fragment of said nucleic acid. A functional fragment of said nucleic acid should be taken to mean a fragment of the gene comprising said nucleic acid(s) coding for the DXPS enzyme or said isoprenoid or a functional equivalent, derivative or a

35

- non-functional derivative such as a dominant negative mutant, or bioprecursor thereof. For example, it would be readily apparent to persons skilled in the art that nucleotide substitutions or deletions may be made using routine techniques, which do not affect the protein sequence and subsequent functioning of the DXPS enzyme and/or isoprenoid producing proteins encoded by said nucleic acid(s).
- 10 The DXPS enzyme expressed or the isoprenoid produced by said transgenic cell, tissue or organism or a functional equivalent or bioprecursor of said protein also forms part of the present invention.
- 15 The recombinant DNA molecules or vectors of the invention can be introduced into the plant cell in a number of recognised ways in the art and it will be appreciated that the choice of method used might depend on the type of plant, i.e. monocot or dicot, targeted for transformation. Suitable methods of transforming plant cells include microinjection (Crossway et al. (1986) BioTechniques 4:320-334), electroporation (Riggs et al. (1986) Proc. Natl. Acad. Sci. USA 83:5602-5606, Agrobacterium mediated transformation (Hinchey et al. (1988) Biotechnology 6:915-921) and ballistic particle acceleration (see, for example, Sanford et al., U.S. Patent 4,945,050; and McCabe et al. (1988) Biotechnology 6:923-926).
- 20
- 25
- 30 Alternatively, in the case of an organism, such as a plant, a plastid can be transformed directly. Stable transformation of chloroplasts has been reported in higher plants, see, for example, SVAB et al. (1990) Proc. Natl. Acad. Sci. USA 87:8526-8530; SVAB & Maliga (1993) Proc. Natl. Acad. Sci. USA 90:913-917; Staub &
- 35

Maliga (1993) *Embo J.* 12:601-606. The method relies on particle gun delivery of DNA containing a selectable marker and targeting of the DNA to the plastid genome through homologous recombination. In such methods, plastid gene expression can be accomplished by use of a plastid gene promoter or by trans-activation of a silent plastid-borne transgene positioned for expression from a selective promoter sequence such as that recognised by T7 RNA polymerase. The silent plastid gene is activated by expression of the specific RNA polymerase from a nuclear expression construct and targeting of the polymerase to the plastid by use of a transit peptide. Tissue-specific expression may be obtained in such a method by use of a nuclear-encoded and plastid-directed specific RNA polymerase expressed from a suitable plant tissue specific promoter. Such a system has been reported in McBride *et al.* (1994) *Proc. Natl. Acad. Sci., USA* 91:7301-7305.

The cells which have been transformed may be grown into plants in accordance with conventional methods known in the art. See, for example, McCormick *et al.*, *Plant Cell Reports* (1986), 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting hybrid having the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that the subject phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure the desired phenotype or other property has been achieved.

A host cell, of any plant variety may be employed. Plant species which provide seeds of interest are

particularly useful. For the most part, plants will be chosen where the seed is produced in high amounts, a seed-specific product of interest is involved, or the seed or a seed part is edible. Seeds of interest
5 include the oil seeds, such as oilseed Brassica seeds, cotton seeds, soybean, safflower, sunflower, coconut, palm, and the like; grain seeds, e.g. wheat, barley, oats amaranth, flax, rye, triticale, rice, corn, etc.; other edible seeds or seeds with edible parts
10 including pumpkin, squash, sesame, poppy, grape, mung beans, peanut peas, beans, radish, alfalfa, cococa, coffee, tree nuts such as walnuts, almonds, pecans, chick-peas etc.

15 The invention may be more clearly understood from the following exemplary embodiment described with reference to the accompanying drawings wherein:

Figure 1: is an illustration of the
20 mevalonate-dependant (A) and independent (B) pathways for IPP biosynthesis. Proposed reactions for the biosynthesis of
25 1-deoxy-D-xylulose-5-phosphate from pyruvate and glyceraldehyde-3-phosphate, catalysed by DXPS is as shown inside the box.

Figure 2: is an illustration of structure of
30 plasmids pBSDXPS and pSYDXPS.

Figure 3: is an illustration of an amino acid
sequence alignment of DXP synthases
35 used in the present invention, Synechocystis sp. 6803 (S.s) (GenBank

D90903), *B. subtilis* (B.s) (GenBank D84432) and *E. coli* (E.c) (GenBank AF035440). The consensus line (consen) shows residues conserved in all three sequences (upper case letters) or residues which are identical in two sequences and replaced by an equivalent amino acid in the third sequence (+). The conserved histidine domain putatively involved in proton transfer is over lined and numbered 1. The second over lined domain (2) denotes the consensus thiamin pyrophosphate (TPP)-binding motif.

Figure 4: is a graphic representation of lycopene accumulation in recombinant *E. coli* cultures expressing vector only (\square), *B. subtilis* DXPS (\bullet) and *Synechocystis* sp. 6803 DXPS (Δ). (Data are means \pm S.E.M. from three independent determinations.)

Figure 5: is an illustration of lycopene (open columns) and UQ-8 (shaded columns) content of *E. coli* control cultures (vector only) or expressing exogenous *B. subtilis* dxps (*B. subtilis*), *Synechocystis* sp. 6803 dxps (sp. 6803) or *A. thaliana* hmgr1 (HMGR1) genes. (Data are means (S.E.M. from three independent determinations.)

EXAMPLE 1

Materials and methods

5 Bacterial strains, plasmids, and culture conditions.

E. coli strain XL1-Blue (Stratagene) was used for gene cloning and expression of plasmids. *E. coli* was grown in Luria Broth media [18] at 37°C on a rotary shaker
10 at 250 rpm (unless otherwise stated). Ampicillin (100 µg/ml), chloramphenicol (50 µg/ml) and 1.0 mM isopropyl-β-D-thiogalactoside (IPTG) (all purchased from Sigma) were added as required. Plasmid pBluescript (Stratagene) was used as a vector for both
15 cloning and expression studies. *Synechocystis* sp. PCC 6803 was obtained from the Institute Pasteur (Paris) and grown in BG11 medium [19] supplemented with 0.5% glucose at 30°C and 2,000 lux. *Bacillus subtilis* strain PY79 DNA was a kind gift from P. Wakeley (Royal
20 Holloway, University of London). The construction of plasmid pACCRT-EIE, which expresses the *E. uredothora* *crtE*, *crtB* and *crtI* genes necessary for lycopene biosynthesis in *E. coli* cells into which it has been introduced, has been described previously [20]. The
25 plasmid used for the expression of HMGR1 cloned into pBluescript (pHMGR1) has also been described elsewhere [21].

Recombinant DNA techniques

30

All recombinant DNA techniques were performed by standard methods [22] or according to suppliers instructions. Genomic DNA was extracted from all organisms using the Qiagen Genomic-tip 20/G kit.

35

Cloning of dxps genes

Based on the nucleotide sequence of ORF sll1945 from the genome database for *Synechocystis* sp. PCC 6803 [23], primers were designed to clone the putative dxps gene by polymerase chain reaction (PCR). The forward primer 5'-GTCCCAATCCACCATGCACATCAG-3' overlaps the beginning of the coding sequence. The reverse primer 5'-CCCTCGACAAATGCAAAATGTATC-3' lies outside the stop codon of the gene. A PCR (25 cycles) using Pfu DNA polymerase (Stratagene) produced a DNA fragment of the expected size (~1.9 kb). Subsequent sequencing of the fragment confirmed the product to be the ORF sll1945. The *B. subtilis* dxps gene was also cloned by PCR using primers designed to amplify the gene encoding the product YqiE, identified in the *Bacillus subtilis* genome database [24]. The forward primer 5'-GATCCGCTATGGATCTT TTATC-3' contains a modified base substitution at the predicted start codon (underlined) for improved expression in *E. coli*. The reverse primer 5'-ATCTAATCGTTCTTTCTTTGAC-3' lies outside the stop codon of the dxps gene. After PCR (25 cycles) a DNA product of the expected size (~1.9 kb) was obtained, and when sequenced proved to be identical to the gene encoding the product YqiE. The PCR products from both reactions were treated with Taq DNA polymerase (GibcoBRL) at 72°C for 10 min to synthesise blunt ended fragments. The fragments were then cloned into the EcoRV site of the pBluescript vector (Stratagene) using T4 DNA ligase (Fermentas) (Fig. 2).

In vitro DXP synthase assay

E. coli XL1-blue cells, transformed with the appropriate plasmid, were grown at 37°C in Luria

Broth medium with appropriate antibiotics to an $OD_{620\text{ nm}}$ of 0.6, and induced by the addition of 1.0 mM IPTG at 28°C for two hours. Bacteria were harvested by centrifugation (6,000g for 10 min) and washed in
5 buffer A (100 mM Tris-HCl (pH 7.5), 1 mM dithioreitol, 0.3 M sucrose). Cells were resuspended to their original volume in buffer B (100 mM Tris (pH 8.0), 1 mM dithioreitol, 0.1 mM phenylmethanesulphonyl fluoride, 1 µ/ml pepstatin,
10 1 µg/ml leupeptin, 1 mg/ml lysozyme). The cells were then incubated at 30°C for 15 min with gentle agitation, and then disrupted by brief sonication at 4°C. The supernatant was recovered and the protein concentration determined using the Bradford assay
15 [25].

An aliquot of the supernatant (100 µl) was transferred to an Eppendorf tube along with 100 µl of assay buffer containing 100 mM Tris (pH 8.0), 3 mM ATP, 3 mM Mn^{2+} ,
20 3 mM Mg^{2+} , 1 mM KF, 1 mM thiamine diphosphate, (0.1%) Tween 60, 0.6 mM mDL-glyceraldehyde-3-phosphate, 30 µM [2- ^{14}C]pyruvate (0.5 µCi). The mixture was incubated for 2 hours at 30°C with gentle agitation. The reaction was stopped
25 by heating the mixture at 80°C for 3 min. After centrifugation at 13,000 g for 5 min, the supernatant was transferred to a clean tube and evaporated to dryness. The residue was resuspended in methanol (50 µl) and loaded onto a TLC plate (silica gel 60).
30 Chromatograms were developed in *n*-propyl alcohol/ethyl acetate/H₂O (6:1:3 v/v/v).

Enzyme assays were performed with extracts of induced cells expressing either *Synechocystis* sp. PCC 6803 or
35 *B. subtilis* DXPS, as opposed to control assays in

which cells contained only the pBluescript vector without insert. TLC analysis of assays expressing one of the dxps clones exhibited a major band (R_f 0.14) assumed to be DXP which was not observed in the controls. Quantification of ^{14}C -labelled DXP was achieved by isolation of the reaction product on TLC. The DXP band was scraped off the plate, eluted from the silica using methanol and quantified by liquid-scintillation counting. Enzymatic dephosphorylation of the assay products resulted in the formation of 1-deoxy-D-xylulose (DX), when analysed on TLC (R_f 0.50). When non-radioactive pyruvate was used in the assay, the DXP (R_f 0.12 stained purple) and DX (R_f 0.47 stained blue) were identified by staining with p-anisaldehyde/sulphuric acid (3:1). The DXP co-chromatographed with authentic, chemically synthesised DXP which stained purple also. The reaction substrates pyruvate (R_f 0.36 stained yellow), DL-glyceraldehyde-3-phosphate (R_f 0.15 stained orange) and D-glyceraldehyde (R_f 0.74 stained orange) were also observable using this TLC system. In reactions where the assay products were dephosphorylated no DXP was observed on TLC only DX.

Quantification of lycopene and ubiquinone QB-8 in *E. coli*

Bacterial growth was determined from the $\text{OD}_{620 \text{ nm}}$. Dry cell weight was calculated from known volumes of culture harvested by centrifugation at 13,000 g for 5 min, washed once with water and recentrifuged. The cells were lyophilised overnight and the weight of the dried cell pellet determined. The lycopene content of the cells was determined by harvesting aliquots of *E. coli* cells by centrifugation at 13,000 g for 5 min and

washing once in water followed by recentrifuging. The cells were resuspended in acetone (200 μ l) and incubated at 68°C for 5 min in the dark. The samples were centrifuged again 13,000 g for 10 min and the acetone supernatant containing the lycopene was placed in a clean tube. The extract was evaporated to dryness under a stream of N₂ and stored at -20°C in the dark. The lycopene content of the extracts was determined by visible light absorption spectra using a Beckman DU Series 7000 diode array spectrometer. Spectra were recorded in acetone using an A_{1cm}^{1%} of 3450 [26].

UQ-8 was extracted from cells based on the methods of Yoshida et al. [27]. Cells were collected by centrifugation, washed once with water and then lyophilised overnight. The dried pellet was extracted in n-propanol (3 ml) and of n-hexane (5 ml) containing 15 μ g of UQ-10 as an internal standard, by disruption of the cells using a pestle and mortar. The solvent phase and that obtained by the second extraction from the aqueous phase n-hexane (3 ml) were combined and evaporated to dryness under N₂. The residue was resuspended in ethanol and analysed by reversed phase HPLC as described previously [28]. Peaks were identified by comparing their elution profiles with standards for UQ-7, UQ-9 and UQ-10. A standard of UQ-8 was not available, and the UQ-8 peak was identified by its elution profile relative to those of the other standards [29].

Cloning of the dxps genes

The cloning of dxps and the characterisation of the gene product, DXPS, from *E. coli* has recently been

reported by two research groups [11,12]. The gene product was shown to exhibit DXP synthase activity, which is considered as the first reaction of the mevalonate-independent pathway for IPP biosynthesis (Fig. 1) [5]. Based on the *E. coli* dxps nucleotide sequence homologs of the gene were identified in the eubacterial genomes of *B. subtilis* and *Synechocystis* sp. PCC 6803. The open reading frame sll1945 in the *Synechocystis* sp. 6803 genome was cloned by PCR, ligated into the vector pBluescript, and designated pSYDXPS (Fig. 2). The gene extends over 1920 bp and contains an open reading frame encoding a polypeptide of 640 amino acids, with a predicted molecular mass of 69 kDa. The dxps homolog in the *B. subtilis* genome was identified as the ORF encoding the product YqiE. It was cloned by PCR, and introduced into pBluescript to generate plasmid pBSDXPS (Fig. 2). The gene extends over 1899 bp and encodes a polypeptide of 633 amino acids with a predicted molecular mass of 70 kDa.

The amino acid sequence of the DXPS proteins of *Synechocystis* sp. 6803 and *B. subtilis* exhibited significant similarity to each other over their entire length (47% identities) and to the *E. coli* DXPS (*B. subtilis* (44 % identities) and *Synechocystis* sp. 6803 (46 % identities)) (Fig. 3). All three polypeptides share two conserved domains; one thought to be involved in thiamin binding [30] and a histidine residue postulated to participate in proton transfer [31], both of which are detailed in Fig. 3. The existence of a thiamin-binding domain in each of the polypeptides explains the cofactor requirement of thiamin for DXPS activity [12]. The high degree of polypeptide sequence identity, particularly the distribution of conserved domains, in all three

indicates that they all encode DXPS or a closely related gene product.

Quantification of lycopene and UQ-8 in *E. coli*
5 transformants

Cells of *E. coli* transformed with pACCRT-EIB [20] are pigmented pink due to the accumulation of lycopene. *E. coli* cells engineered to produce lycopene, were
10 transformed with either pBSDXPS, pSYDXPS, pHMGR, or pBluescript to act as a control, to monitor the effect on lycopene biosynthesis when exogenous DXPS was expressed in the cells. The *E. coli* were grown in
15 50 ml cultures at 30°C with induction by IPTG for 48 hours, by which time they had reached the stationary phase of growth. Figure 4 shows the accumulation of lycopene in the cultures during the 48 hour culture period. The graph clearly demonstrates that the *E. coli* cultures expressing exogenous dxps accumulated
20 lycopene at a much greater rate than the control culture. The final lycopene content of the recombinant dxps strains was approximately double that of the control (Fig. 5). A similar increase was also obtained in *E. coli* cells engineered to produce the
25 colourless carotenoid phytoene (data not shown). Alterations in the endogenous levels of isoprenoids were determined by measuring the ubiquinone content of the cells. In *E. coli*, the major quinones encountered are ubiquinone (UQ-8) and menaquinone
30 (MK-8) [32]. Ubiquinone is a major component of the aerobic respiratory chain. It is estimated that there are approximately 50 molecules of ubiquinone for each of the oxidation complexes in *E. coli* [33]. By measuring an end product which is produced in
35 relatively large quantities, it was conjectured that

alterations in the rates of biosynthesis could be readily detected. The UQ-8 content of the recombinant dxps strains was 1.5 times greater than the controls (Fig. 5). Lycopene and UQ-8 levels were measured in
5 *E. coli* transformed with hmgr1 from *A. thaliana*, to monitor if this caused any alterations in the isoprenoid content of the cells. Expression of the *A. thaliana* hmgr1 cDNA had no effect of the levels of lycopene nor UQ-8 in the cells (Fig. 5).

10

The results show that increased expression of DXPS leads to increased lycopene and UQ-8 levels in the recombinant *E. coli* cells. This indicates that increasing the rate of DXP synthesis, the initial
15 reaction in the mevalonate-independent pathway for IPP biosynthesis, elevates isoprenoid production. In contrast, expression of hmgr1 had no effect on isoprenoid biosynthesis, suggesting that mevalonate dependent IPP biosynthesis has little or no role in
20 IPP synthesis in *E. coli*. Similarity searches of the *E. coli* genome data base for proteins of the mevalonate-dependent IPP biosynthesis pathway failed to identify any possible homologs in the genome suggesting that this pathway is probably absent in
25 this organism.

In vitro enzyme activity

The increased levels of carotenoids and UQ-8 in *E. coli* expressing exogenous DXPS were hypothesised to be
30 due to increased DXPS enzymatic activity in the cells. This was confirmed by preparing cell homogenates from recombinant *E. coli* strains after induction with IPTG. Reaction products were measured over a two hour
35 period, separated by TLC and quantified by

liquid-scintillation counting. The major product obtained from the reaction co-chromatographed with chemically-synthesised DXP. This confirms DXP as the major reaction product in the assay. The putative DXPS function of *B. subtilis* ORF encoding the product YqiE and *Synechocystis* sp. 6803 ORF sll1945 has been established by these results. Table 1 shows the specific activity of DXPS in the recombinant *E. coli* strains. The results show that DXPS activity was increased in *E. coli* expressing endogenous dxps genes. This increase was greatest in homogenates containing the *B. subtilis* DXPS, where a 2.0 fold increase was observed compared to the controls. Homogenates containing the *Synechocystis* sp. 6803 DXPS exhibited a 1.8 fold increase compared to control reactions. Therefore, increased DXPS activity in *E. coli* appears to be responsible for the increased levels of carotenoids and UQ-8 observed in the transgenic strains. The relative increases in carotenoid levels between *E. coli* cultures expressing plasmids pSYNDXSP and pBSDXPS closely resemble the increases observed in the in vitro studies. This suggests that there is a direct relationship between DXPS activity and the carotenoid content of the cells. This is not the case for UQ-8 where increases in the levels of UQ-8 are more restricted, which could be due to a rate-limiting reaction later in the UQ-8 biosynthesis pathway [34]. The results support the hypothesis that increased DXPS activity in *E. coli* results in increased levels of carotenoids and UQ-8. These data suggest that isoprenoid levels in *E. coli* can be increased by enhancing DXPS activity.

Isoprenoids constitute a large group of compounds many of which are of high economic value. The condensation

of (hydroxy)thiamin, derived from the decarboxylation of pyruvate, with glyceraldehyde-3-phosphate to yield 1-deoxy-D- xylulose-5-phosphate, is considered to be the first reaction in the mevalonate-independent pathway for IPP and ultimately isoprenoid biosynthesis. The data presented show that increasing the rate of DXP synthesis in *E. coli* results in increased isoprenoid biosynthesis. This finding can therefore be utilised to optimise the industrial production of isoprenoids from bacteria. The manipulation of enzyme activities important in the biosynthesis of specific isoprenoids in concert with DXPS may be employed to bioengineer the production of specific, high value isoprenoids in *E. coli* or another suitable cell or organism such as in plants where increased isoprenoid production could be used for improving crop flavour, fragrance and colour. Alternatively, crops could be engineered to produce increased concentrations of isoprenoids with pharmaceutical and/or nutritional properties.

TABLE 1. DXP synthase activity in *E. coli* homogenates

5	Specific activity		Fold increase
	nmol/min/mg protein		in activity
	Control	5.8 \pm 0.07	1.0
	<i>B. subtilis</i>	11.5 \pm 0.58	2.0
	<i>Syn. sp. 6803</i>	10.4 \pm 0.24	1.8

10

References

- 5 [1] Dictionary of Natural Products on CD-ROM (v. 5.1). (1996) Chapman and Hall.
- [2] McCaskill, D. and Croteau, R. (1998) TIBTECH, 16, 349-355.
- 10 [3] Horbach, S., Sahm, H. and Welle, R. (1993) FEMS Microbiol. Lett. 111: 135-140.
- [4] Rohmer, M., Knani, M., Simonin, P., Sutter, B. and Sham, H. (1993) Biochem. J. 295, 517-524.
- 15 [5] Rohmer, M., Seeman, M., Horbach, S., Bringer-Meyer, S., Sahm, H. (1996) J. Am. Chem. Soc. 118, 2564-2566.
- 20 [6] Schwender, J., Seeman, M., Lichtenthaler, H. K. and Rohmer, M. (1996) Biochem. J. 316, 73-80.
- [7] Eisenreich, W., Menhard, B., Hylands, P. J., Zenk, M. H., Bacher, A. (1996) Proc. Natl. Acad. Sci. USA 93, 6431-6436.
- 25 [8] Lichtenthaler, H. K., Schwender, J., Disch, A. and Rohmer, M. (1997) FEBS Lett. 400, 271-274.
- [9] Eisenreich, W., Sagner, S., Zenk, M. H. and Bacher, A. (1997) Tetrahedron Lett. 38, 3889-3892.
- 30 [10] Zeidler, J. G., Lichtenthaler, H. K., May, H. U. and Lichtenthaler, F. W. Z. (1997) Naturforsch. 52c, 15-23.
- 35

- [11] Lois, L. M., Campos, N., Putra, S. R., Danielsen, K., Rohmer, M. and Boronat, A. (1998) Proc. Natl. Acad. Sci. USA 95, 2105-2110.
- 5 [12] Sprenger, G. A., Sch+rken, U., Wiegert, T., Grolle, S., de Graaf, A. A., Taylor, S. V., Begley, T. P., Bringer-Meyer, S. and Sahm, H. (1997) Proc. Natl. Acad. Sci. USA 94, 12857-12862.
- 10 [13] Lange, M. B., Wildung, M. R., McCaskill, D. and Croteau, R. (1998) Proc. Natl. Acad. Sci. USA 95, 2100-2104.
- 15 [14] Bouvier, F., d'Harlingue, A., Suire, C., Backhaus, R. A. and Camara, B. (1998) Plant Physiol. 117, 1423-1431.
- 20 [15] Mochs, C. P., Tan, L., Cunningham, F. X. and Della Penna, D. 9th International Conference on Arabidopsis Research, University of Wisconsin-Madison, USA, June 24-29, 1998 (abstr).
- 25 [16] Mandel, M. A., Feldmann, K. A., Herrera-Estrella, L., Rocha-Sosa and M., Leon, P. (1996) Plant J. 9, 649-658.
- 30 [17] Takahashi, S., Kuzuyama, T., Watanabe, H. and Seto, H. (1998) Proc. Natl. Acad. Sci. USA 95, 9879-9884.
- [18] Miller, J. H. (1972) Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

- [19] Rippka, R., Deruelles, J., Waterbury, J. B.,
Herdman, M. and Stanier, R. Y. (1979) J. Gen.
Microbiol. 111, 1-61.
- 5 [20] Misawa, N., Satomi, Y., Kondo, K., Yokoyama, A.,
Kajiwara, S., Saito, T., Ohtani, T. and Miki, W.
(1995) J. Bacteriol. 177, 6575-6584.
- 10 [21] Caelles, C., Ferrer, A., Balcells, L., Hegardt,
F. G and Boronat, A. (1989) Plant Mol Biol. 13,
627-638.
- 15 [22] Sambrook, J., Fritsch, E. F. and Maniatis, T.
(1989) Molecular cloning : A Laboratory Manual,
2nd Ed., Cold Spring Harbor Laboratory, Cold
Spring Harbor, NY.
- 20 [23] Kaneko, T., Sato, S., Kotani, H., Tanaka, A.,
Asamizu, E., Nakamura, Y., Miyajima, N.,
Hirosawa, M., Sugiura, M., Sasamoto, S., Kimura,
T., Hosouchi, T., Matsuno, A., Muraki, A.,
Nakazaki, N., Naruo, K., Okumura, S., Shimpo, S.,
Takeuchi, C., Wada, T., Watanabe, A., Yamada, M.,
Yasuda, M. and Tabata, S. (1996) DNA Res. 3,
25 109-136.
- 30 [24] Mizuno, M., Masuda, S., Takemaru, K., Hosono, S.,
Sato, T., Takeuchi, M. and Kobayashi, Y. (1996)
Microbiol. 142, 3103-3111.
- [25] Bradford, J. M. (1976) Anal. Biochem. 72,
248-254.
- 35 [26] Zweig, G., Sherma, J. (1988) CRC Handbook of
Chromatography, Vol. 1., Fat-Soluble Pigments,

CRC Press, Boca Raton, FL.

- 5
- [27] Yoshida, H., Kotani, Y., Ochiai, K., Araki, K.
(1998) J. Gen. Appl. Microbiol. 44, 19-26.
- [28] Van Breeman, R. B. (1995) Anal. Chem. 67,
2004-2009.
- 10
- [29] Collins, M. (1985) Meths. Microbiol. 18, 329-366.
- [30] Hawkins, C. F., Borges, A. and Perham, R. N.
(1989) FEBS Lett. 255, 77-82.
- 15
- [31] Lindqvist, Y., Schneider, G., Ermler, U. and
Sundström, M. (1992) EMBO J. 11, 2373-2379.
- [32] Collins, M. D. and Jones, D. (1981) Microbial.
Rev. 45, 316-354.
- 20
- [33] Wallace, B. J. and Young, I. G. (1977) Biochim.
Biophys. Acta 461, 75-83.
- [34] Hemmi, H., Ochnuma, S., Nagaoka, K. and Nishino,
T. (1998) J. Biochem. 123, 1088-1096.

25

30

35

Claims

1. A method of manipulating isoprenoid expression in a cell or organism having a mevalonate independent isopentyl diphosphate synthesising pathway, which method comprises altering the activity of the enzyme 1-deoxy-D-xylulose-5-phosphate synthase (DXPS), or a functional equivalent, derivative or bioprecursor thereof.
2. A method according to claim 1 wherein said isoprenoid production is increased by enhancing the activity or expression of said DXPS or lowered by inhibiting the activity or expression of said DXPS enzyme.
3. A method according to claim 2 wherein said enhanced DXPS activity occurs by transformation of said cell or organism with a vector comprising a nucleic acid molecule encoding said DXPS operably linked to an expression control sequence and optionally a reporter molecule
4. A method according to claim 3 wherein said DXPS encoded by said nucleic acid sequence is endogenous to said cell or organism.
5. A method according to claim 3 or 4 wherein said vector comprises one or more nucleic acid sequences encoding a polypeptide(s) capable of producing a desired isoprenoid in said cell or organism.
6. A method according to claim 3 or 4 wherein said cell or organism is transformed with a further

vector comprising one or more nucleic acid sequences encoding a polypeptide(s) capable of producing a desired isoprenoid.

5 7. A method according to any preceding claim wherein said cell is any of a bacterial, yeast or algal cell.

8. A method according to claim 7 wherein said
10 bacterial cell is *E. coli*.

9. A method according to any preceding claim wherein said organism is a plant.

15 10. A method according to any of claims 3 to 9 wherein said vector comprising said nucleic acid sequence(s) encoding said DXPS and/or said polypeptide(s) capable of producing said isoprenoid further comprises a nucleic acid sequence of either a
20 tissue specific promoter and/or encoding a plastid transit peptide.

11. A method according to any of claims 5 to 10 wherein said desired isoprenoid is one conferring a
25 nutritional benefit or an aesthetic phenotype.

12. A method according to claim 11 wherein said isoprenoid comprises any of the carotenoids, vitamins E, B1 or B6, chlorophylls, phenylquinones or
30 diterpenes.

13. A cell or organism which has a mevalonate independent IPP biosynthetic pathway and which is transformed or transfected with a vector comprising a
35 nucleic acid sequence encoding DXPS or a functional

equivalent, derivative or bioprecursor thereof
operably linked to an expression control sequence.

5 14. A cell or organism according to claim 13
 wherein said vector further comprises a nucleic acid
 molecule encoding a reporter molecule.

10 15. A cell or organism according to claim 13 or
 14 which further comprises a vector comprising one or
 more nucleic acid sequences encoding one or more
 polypeptides capable of producing a desired
 isoprenoid.

15 16. A cell or organism according to claim 15
 wherein said desired isoprenoid comprises any of the
 carotenoids, vitamin E, B1 or B6, chlorophylls,
 phenylquinones, or diterpenes.

20 17. A method of identifying a compound which
 modulates isoprenoid activity or expression said
 method comprising contacting said compound to be
 tested with a molecule which is a component of the
 mevalonate independent IPP biosynthetic pathway and
 which molecule undergoes a reaction catalysed by DXPS
25 activity in the presence of an appropriate reactant,
 in the presence of DXPS or a functional equivalent
 thereof and monitoring the yield of a product of the
 reaction when compared to the same reaction performed
 in the absence of the compound to be tested.

30

 18. A method according to claim 17 wherein said
 molecule comprises pyruvate and said appropriate
 reactant comprises glyceraldehyde-3-phosphate or vice
 versa.

35

19. A compound identified as a modulator of isoprenoid activity or expression according to the method of claim 17 or 18.

5 20. A compound according to claim 19 which comprises an inhibitor of DXPS or a functional equivalent of DXPS.

10 21. A compound according to claim 20 for use as a medicament or as a herbicide.

15 22. Use of a compound according to claim 20 in the preparation of a medicament to treat bacterial associated disease.

20 23. A pharmaceutical composition comprising a compound according to claim 20 together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

24. A herbicidal composition comprising a compound according to claim 20.

25 25. A transgenic cell, tissue or organism having a mevalonate independent IPP biosynthetic pathway which cell, tissue or organism comprises at least one transgene capable of expressing DXPS or a functional equivalent, derivative or bioprecursor thereof.

30 26. A transgenic cell, tissue or organism according to claim 25, which comprises at least one additional copy of any of the nucleic acid sequences identified in Figure 3, or the complement thereof.

35 27. A transgenic cell, tissue or organism

according to claim 25 or 26, further comprising a
transgene capable of expressing one or more
polypeptides capable of producing a desired
isoprenoid, or a functional equivalent, derivative or
5 bioprecursor thereof.


28. A transgenic cell, tissue or organism
according to any of claims 25 or 27, wherein said
organism is a plant.

10

29. A transgenic cell tissue or organism
according to claim 28, wherein said plant is of the
Lycopersicon spp.

15 30. Progeny of the organism according to any of
claims 25 to 29.

Figure 1.






.

.

.

.

Figure 2.





1

S.s 1 -----HHSIELTSPNDKAGLSIREBVSRCIGZHQLTVAISGELQPGVYVSEHSTYSLDLDKRVINTEHGAEPREH
B.s 1 -----MDLLSIGDPSYKMSIDKHELEDEIFLITSLNAGGHIQGNSEVNTYHKKRTNSPFGKLEKPSVVALTIT
E.c 1 HSPGIAKYPIALVLDSTQVLLPKESITCLLRYLLSSVSRSSVAGSGTSTHTVINTPFYOLLNLSAAPHRIIT
Consen + + L+ ++ +L +++ +R + +++ S+GH ++L3+VALTVAL+ + D +MDVGHQ+Y EK ITC

2

S.s 91 ENHDPDRLDQDVAOTLRSERPFQHFCAHTATSEAGTAAKQDAKQCTPKVYSIDGKILGHEMLFZYHAPILPSTRLVTH
B.s 91 EKQZFMILKYNKSLGPPFSSGZHYVETHTSSSTSGAGKMAADNDINDTITIPIDKALDQVHSHLHSTPKKODMI
E.c 91 SPCKIGGIPVGGSPFFWGGESITVLSVNGHSTAGLITVAZPGGQKRTVCVQSTIIGASPEHGLAQRDPCKL
Consen R + T+RQ G+ + R+2S+ D OH+ST5+S++ G+A A + +G + + +IGGA+T+GA+EA WH G+ + VILN

S.s 181 DNHEHSSTPHEHISRYLKNVXLSSPHQFLTDLHSEQISRLSFVGDSTPDKRVVZGSLVLPKPVAVIEEHWQFHEISLQD
B.s 181 DHEHFAHPIHRSGLRLTACKYQWVMDLRYLPKQILAVGGCAATAKRVDSLTHLT--SQTPELLESTELSVGHESTHEH
E.c 181 DNHEHSSTPHEHLLNTHAQLLSGCLYSSLRZGGKVKV7SGVSPKRELKRTLEHI---RGAVDP--ETLLEELGNTIHEVMDVGLG
Consen DNEMSI+ NYGA+ L + + + + + ++ P + L E++ K ++V G +KELGF Y GP+DQH+ LI

S.s 271 DTFKQAKKVPFVVFVVSITFDLQDLERQQVGYHAGSPNLSGKAYPSSKPKPSTKVKYAHTLTITAKENPNIVGTAATATSGI
B.s 271 ENLQYAKKQITGVLLVIFSGGHPF--TITOTWBTGPKYKINTGDFPKPAAAHSGSLVSGTVGRAREDRARIVATPQVPSK
E.c 271 TELKQDLKSPQFLDQGLSGSPKSPITITPAVFKTDPSS--GCLFSSGGLSPYKIFGDLCEATAPONKMAHDPKRLSG
Consen +++ + GF ++H+ T+KQ+GY AE+D + +++ PS+S + + A ++ ++IT+AH G+

S.s 361 DKLQAKLKKQYVWQVQSSHEV--LGGCACTPQVVEVSTFELSGELQIIEVVCILPLTPCLDRAIPEAGDPTNCAHTIAYLC
B.s 361 EGPAKCTPDQVSGEHEHDAAGANACGANSYLKHTSLGPAKGVVHICONASHTIGTEETDINQ--HCVTEIAFYSE
E.c 361 VETSPKPSQRTYFAGAGKAVVTP--GLIGCKHIVVLEH--KATVYLSVALKLPALFAEETVAT--TQEGATQLSYLK
Consen + ++P++ +DV+IAZGHA+T AA++A G +P +AITSTFLQ+YDQ+ ED++ Q+ V++ +DRAG+VQADG TXGG +E+---R

S.s 451 ENNLALAKKQKAPLQVGVVNTQCAINAYVNTGSIITPLMEZGWFELZHQAILSEEDVLLGYESMTYFPLCTEELHSEEG
B.s 451 ENNLALAKKQKAPLQVGVVNTQCAINAYVNTGSIITPLMEZGWFELZHQAILSEEDVLLGYESMTYFPLCTEELHSEEG
E.c 451 ENNLALAKKQKAPLQVGVVNTQCAINAYVNTGSIITPLMEZGWFELZHQAILSEEDVLLGYESMTYFPLCTEELHSEEG
Consen IP+V+M P+DE E ++H+ T+ Y G+ A+R+PRGN+ GV ++ IG+ + R G + +L +G+ A AE L

S.s 541 EATVNAHSEVSELTTELLPLAZRIGKVT--EGGLNCGYHAVAALMDNNVLY--SLGLEVVKLVDEATPEGSTVDLSTCPAQACN
B.s 541 SVTVNACHHIAHIXONKSLKEGLPILQGVAVLEGG--ESTILEPAGQGEYET--DRNLESTFIEGSSVALLEEIEHFKQTVAN
E.c 541 -ATV--MDHSEV--DRAILLQDASHALVTEANDEPAISGTVNAHKKPV--GVNLNDEPFIQGTQEDRAILLQDASHAK
Consen + +V+ RJ+KP+D ++ ++ EK + GG GS + I P + G YD ++ ++ ++GL +

S.s 601 DASLFXETETESVYAGVS
E.c 601 DELLFPKTEKICG-----
E.c 601 IRAWLA-----
Consen I



.

.

.

.

Figure 4.





Figure 5





4
3
2
1

4
3
2
1

4
3
2
1

4
3
2
1